Please assess the completion status of the following clinical trial:

Trial Title: Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with open-angle glaucoma or ocular hypertension and, in the opinion of the Investigator, are insufficiently controlled on monotherapy or are currently on multiple IOP-lowering medications.~* Meet qualifying IOP entry criteria.~* Able to understand and sign an informed consent form.~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential if pregnant, test positive for pregnancy at Screening visit, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.~* Severe central visual field loss.~* Can not safely undergo the initial washout period and discontinue use of all IOP-lowering ocular medication(s) for the minimum specified period prior to Eligibility Visit 1.~* Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen equivalent).~* Chronic, recurrent or severe inflammatory eye disease.~* Ocular trauma within the preceding 6 months.~* Ocular infection or inflammation within the preceding 3 months.~* Clinically significant or progressive retinal disease.~* Other ocular pathology.~* Intraocular surgery within the 6 months prior to entry.~* Ocular laser surgery within the 3 months prior to entry.~* Any abnormality preventing reliable applanation tonometry.~* Any other conditions which would make the patient, in the opinion of the Investigator, unsuitable for the study.~* Recent use of high-dose (\>1 gram daily) salicylate therapy.~* Recent, current, or anticipated treatment with any medication that augments adrenergic responses, or precludes use of an alpha-adrenergic agonist.~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brinz/Brim (Type: EXPERIMENTAL): Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
- Brinz+Brim (Type: ACTIVE_COMPARATOR): Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).